Physician profile
Michael A Welsh
NPI 1235122763
$4,734.95
in general payments reported to CMS, 2019-2025
33 companies · $57.59 in 2025
The $57.59 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $946 · 2021: $637 · 2022: $516 · 2023: $895 · 2024: $751 · 2025: $57.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.82 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $592.28 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $522.61 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.61 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $355.13 | 2019-2023 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $248.70 | 2019-2022 | |
| Pfizer INC. | $247.32 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $180.73 | 2020-2024 | Trintellix |
| Glaxosmithkline, LLC. | $170.43 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $165.69 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $154.63 | 2019-2021 | |
| Allergan, INC. | $147.96 | 2020 | |
| Daiichi Sankyo INC. | $111.24 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $90.05 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $84.29 | 2023-2024 | Quviviq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $76.03 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $75.43 | 2019-2021 | |
| Abbott Laboratories | $58.43 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $42.05 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $32.78 | 2023 | Sunosi |
| Horizon Therapeutics Plc | $29.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.45 | 2023 | Eliquis |
| Exact Sciences Corporation | $25.10 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $24.71 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $19.25 | 2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.93 | 2020 | |
| Amgen INC. | $18.55 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.12 | 2022 | |
| Genentech USA, INC. | $17.98 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.79 | 2021 | |
| Amarin Pharma, INC. | $15.78 | 2019 | |
| Itamar Medical INC | $14.64 | 2022 | |
| Adlon Therapeutics L.P. | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Welsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.